BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11785993)

  • 21. Management of multivessel coronary disease after ST elevation myocardial infarction treated by primary angioplasty.
    Rigattieri S; Biondi-Zoccai G; Silvestri P; Di Russo C; Musto C; Ferraiuolo G; Loschiavo P
    J Interv Cardiol; 2008 Feb; 21(1):1-7. PubMed ID: 18086133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
    Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hirudin in acute coronary syndromes.
    van de Loo A; Bode C
    Semin Thromb Hemost; 2002 Oct; 28(5):459-66. PubMed ID: 12420242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Two year follow-up of acute ischemic syndrome without ST elevation].
    Tan HQ; Zhu J; Liang Y; Zhang Y; Liu LS;
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):184-8. PubMed ID: 15854465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery.
    Gurfinkel EP; Perez de la Hoz R; Brito VM; Duronto E; Dabbous OH; Gore JM; Anderson FA;
    Int J Cardiol; 2007 Jun; 119(1):65-72. PubMed ID: 17045681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender differences in the outcome of cardiac interventions.
    Tillmanns H; Waas W; Voss R; Grempels E; Hölschermann H; Haberbosch W; Waldecker B
    Herz; 2005 Aug; 30(5):375-89. PubMed ID: 16132240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
    Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris.
    Hirsch A; Verouden NJ; Koch KT; Baan J; Henriques JP; Piek JJ; Rohling WJ; van der Schaaf RJ; Tijssen JG; Vis MM; de Winter RJ
    Am J Cardiol; 2009 Aug; 104(3):333-7. PubMed ID: 19616663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of percutaneous coronary intervention in non ST-elevation acute coronary syndromes on prescription of secondary prevention medications. Data from the S-Témoin Registry].
    Danchin N; Thébaut JF; Diévart F; Grenier O; Mihci E; Herrmann MA; Ferrières J
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):30-5. PubMed ID: 17343036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group.
    Am Heart J; 2001 Jan; 141(1):E2. PubMed ID: 11136505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current therapeutic strategies in acute coronary syndrome. New and established drug and interventional therapy].
    Roth M
    MMW Fortschr Med; 1999 Jul; 141(28-29):30-4. PubMed ID: 10897939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
    N Engl J Med; 1996 Sep; 335(11):775-82. PubMed ID: 8778585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    Yusuf S
    Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.